feed,title,long_url,short_url
Benzinga,"Yumanity Cuts 60% Of Its Workforce, Explores Strategic Alternatives",https://benzinga.com/general/biotech/22/02/25691618/yumanity-cuts-60-of-its-workforce-explores-strategic-alternatives,https://bit.ly/3h08MMd
Benzinga,Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer,https://benzinga.com/general/biotech/22/02/25690259/alkermes-nemvaleukin-shows-encouraging-anti-tumor-activity-in-pretreated-kidney-cancer,https://bit.ly/3oR9UX5
Benzinga,SolarWinds Q4 Earnings Surpass Street View,https://benzinga.com/news/earnings/22/02/25686017/solarwinds-q4-earnings-surpass-street-view,https://bit.ly/3JCRvVE
Benzinga,FDA Sets Up Adcomm To Review Amylyx's ALS Drug Next Month,https://benzinga.com/general/biotech/22/02/25689046/fda-sets-up-adcomm-to-review-amylyxs-als-drug-next-month,https://bit.ly/3GYrLSf
